Blood Test for p-tau217 Predicted Decline Over 12 Years

That is the main finding of an observational study in people, published in 2026 in Alzheimer's & Dementia, the journal of the Alzheimer's Association. The researchers followed 982 community-dwelling older adults in Madrid, Spain, who had no cognitive impairment at the start. Participants were assessed every year for up to 12 years. Because the study observed people rather than assigning a treatment, it shows links, not causes.

The test measures a form of the tau protein in blood, called p-tau217. Tau is one of the two proteins that build up in the brain in Alzheimer's disease. This study used a ratio, written %p-tau217. It compares the altered form of the protein with the unaltered form. According to the authors, this ratio can reduce the effect of factors such as chronic kidney disease and differences in how individuals process proteins. Levels were measured by mass spectrometry, a laboratory method that identifies molecules by their mass.

Participants were placed in four groups using cut-offs set in earlier research: Low (below 2.66%), Intermediate (2.66% to 4.90%), Elevated (4.90% to 7.40%) and High (7.40% or above). The study looked at changes in thinking, brain shrinkage on MRI scans, and progression to mild cognitive impairment (MCI) or dementia.

People in the Elevated and High groups did worse on all three measures. They showed faster cognitive decline and faster shrinkage of the hippocampus, a brain region central to memory. Their risk of progressing to MCI was more than six times higher (hazard ratio above 6.0). Their risk of progressing to dementia was nearly ten times higher or more (hazard ratio above 9.9). The authors adjusted for age, sex, years of education and APOE ε4, a known genetic risk factor.

The reassuring result may matter most for people without symptoms. In the Low group, the negative predictive value at 10 years was 92.2% for any progression. In plain terms, about 92 of every 100 people with a low result had not progressed to MCI or dementia by 10 years. The authors say high negative predictive values suggest the test could help identify low-risk people in the community.

The findings held up in two further checks. Results were similar when p-tau217 was measured with immunoassays, a more widely used lab method, in the same group. They were also similar in an independent group of 1,204 cognitively unimpaired primary care patients in Germany, all over 80, measured with a different immunoassay.

There are limits. The main cohort was a single-center group in Madrid, aged 69 to 85. The authors say future work should test the results in more diverse populations, including younger people, other demographics and different genetic backgrounds. The study also shows risk across groups, not what will happen to any one person. A higher result raises the odds of decline but does not make it certain. The paper does not test whether acting on a result changes outcomes.

The authors conclude that the findings support using plasma p-tau217 in riskstratification strategies for preclinical Alzheimer's disease, in both clinical practice and research. That is their interpretation, not a tested recommendation for routine screening.

This study differs from The Arising's October 11 report on a gut bacteria compound, ImP, linked to faster cognitive decline. That work pointed to a possible future marker and target. This one looks at a blood marker of Alzheimer's pathology itself, and tracks it over a decade.

What to watch next

Studies in more diverse and younger groups, and trials testing whether acting on an early result can delay decline.

Two-Year Fish Oil Trial Finds No Memory or Brain-Shrinkage Benefit Detailed Data Confirm Personalized mRNA Melanoma Vaccine Cut Recurrence Risk 42% Blood Signatures of Fitness Linked to Lower Death Risk in UK Biobank Change in AI Face Age Between Photos Linked to Cancer Survival Untreated Sleep Apnea Linked to 69% Faster Cognitive Decline Over 10 Years Over 80 Nutrition Experts Urge White House to Release Ultra-Processed Food Definition Beetroot Juice and Postmenopausal Heart Oxygen Balance After Hard Exercise: A Small Trial Topical Urolithin A Lowered Eye Wrinkle Depth in Randomized Studies Short Breathing Exercises Blunted Heart Rate and Anxiety Under Stress Aerobic and Resistance Training Ended Up Equal for Type 2 Diabetes Plant and Dairy Protein Shakes Left Blood Chemistry Alike in Adults Over 50 Intensity Relative to Your Own Fitness Better Explained Fitness in Midlife Women Blood Flow Restriction Training Showed No Overall Advantage for Artery Health Cigarette Smoke Disrupts Eye Cell Mitochondria, Pointing to Macular Degeneration Risk Ultra-Processed Food Intake Leaves Distinct Blood Fat and Metabolite Signatures Gut-Made Kidney Toxins Linked to Tiny Brain Bleeds in Mice and Patients Flo App Survey of 17,494 Women Finds Gaps in Perimenopause Knowledge New Aging Framework Names Epigenetic Change the Dominant Driver of Aging Exercise Helps Blood Cancer Patients During Treatment, but Diet Evidence Lags Review: Protein Supplements Often Unnecessary Outside the Lab for Active Adults Ear Vagus Nerve Stimulation Linked to Less Inflammation After Surgery Fasting and Lean Mass Over 45: Short Trials, Small Differences Fragmented Sleep Tracked by Wrist Monitors Linked to More Brain Amyloid at Autopsy Blood Test for p-tau217 Predicted Decline Over 12 Years Steady Aerobic Exercise Raised Fitness on Average in Heart Disease Patients Rising Arterial Stiffness Linked to Progression of Heart-Kidney-Metabolic Disease Brain-Wide Gene Therapy Restored Memory in Alzheimer's and Old Mice Men With Heart and Metabolic Disease Show Faster Epigenetic Aging AI Spotted Heart Disease From Face and Tongue Photos in Small Test